Ratings Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Market Closed - Australian S.E. Other stock markets 02:10:37 2024-05-17 am EDT			5-day change	1st Jan Change
0.145 ^AUD	-6.45%		-3.33%	-27.50%

Apr. 11	Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19%	MT
Mar. 18	Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The stock, which is currently worth 2024 to 0.59 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIGTINCAN HOLDINGS LIMITED	-27.50%	63.78M	-
MODERNA, INC.	+33.63%	50.85B	B-
IQVIA HOLDINGS INC.	-0.09%	42.82B	B
LONZA GROUP AG	+49.62%	42.03B	A
CELLTRION, INC.	-4.96%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B	B
BIO-TECHNE CORPORATION	+8.61%	13.05B	B+
MEDPACE HOLDINGS, INC.	+28.31%	12.16B	C+
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes